Tacrolimus Ophthalmic Solution for the Treatment of Non-infectious Anterior Uveitis
Part of paid clinical trials in Waltham, Massachusetts.
- Sponsor
- Novaliq GmbH
- Study ID
- NCT07285070
- Phase
- PHASE2
- Status
- Recruiting
Conditions
- Non-infectious Anterior Uveitis
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Tacrolimus ophthalmic solution — DRUGhigh and low dose treatment will be compared over 6 weeks treatment
Study Details
The primary objective of the study is to investigate the safety and tolerability of NOV05 eye drops at two concentrations QID in patients with active non-infectious anterior uveitis.
Key Dates
- Start date
- Mar 16, 2026
- Status verified
- Apr 2026
- Primary completion
- Oct 31, 2026
- Completion
- Oct 31, 2026
Study Design
- Enrollment
- 20 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Active Comparator: Tacrolimus ophthalmic solution (high dose)
- Active Comparator: Tacrolimus ophthalmic solution (low dose)
Primary Outcome Measure
Adverse Events [ Time Frame: 8 weeks ]
Central Contacts
- Alice Meides, PhD+49 622150259
Locations (4)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Massachusetts Eye Research and Surgery Institution | Waltham | Massachusetts | 02451 | Megan Mitchell +1 781-647-1431 |
| Metropolitan Eye Research and Surgery Institute | Palisades Park | New Jersey | 07650 | Sachi Desai +1 201-461-3970 |
| Valley Retina Institute, P.A. | McAllen | Texas | 78503 | Alexia Salas +1 956-631-8875 |
| Virginia Eye Consultants | Norfolk | Virginia | 23502 | Alexandria Robinson +1 757-493-3053 |